OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 125,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 125,000 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average price of $1.59 per share, with a total value of $198,750.00. Following the transaction, the chief executive officer now owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost bought 199,072 shares of OPKO Health stock. The stock was purchased at an average price of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Trading Down 1.2 %

NASDAQ OPK opened at $1.59 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock’s fifty day moving average price is $1.53 and its 200-day moving average price is $1.47. The stock has a market cap of $1.09 billion, a P/E ratio of -8.37 and a beta of 1.62.

Analysts Set New Price Targets

OPK has been the subject of a number of research analyst reports. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP increased its holdings in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd purchased a new stake in shares of OPKO Health during the second quarter valued at $1,840,000. Assenagon Asset Management S.A. increased its holdings in OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after buying an additional 876,272 shares in the last quarter. Clearline Capital LP purchased a new position in OPKO Health in the 3rd quarter worth about $1,083,000. Finally, Squarepoint Ops LLC bought a new position in OPKO Health during the 2nd quarter valued at about $592,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.